Read More

Johnson & Johnson Announces First Data From Phase 3 PERSEUS Study Highlighting DARZALEX FASPRO-Based Quadruplet Therapy Regimen Shows Significant Improvement In Outcomes For Patients With Transplant-Eligible Newly Diagnosed Multiple Myeloma

DARZALEX FASPRO®-based induction, consolidation and maintenance regimen reduced risk of progression or death by 58 percent compared to standard of care regimenFirst presentation of data from Phase 3 PERSEUS study

JNJ